Poolbeg Pharma PLC - London-based clinical stage biopharmaceutical firm - Updates on Gilead Sciences Inc’s intentions regarding potential Hookipa Pharma Inc combination. Notes its intention to vote in line with the board of Hookipa in the instance of a formal offer and that it will participate in the proposed concurrent fundraise in an amount up to $8.7 million. Says this is consistent with its existing contractual obligations. Hookipa intends to fundraise up to approximately $30 million. Gilead currently owns a 19% stake in Hookipa. Poolbeg notes that all combination discussions have been non-binding in nature with no certainty present that a formal offer will be made.

Current stock price: 5.40 pence, down 3.6% on Friday afternoon in London

12-month change: down 45%

Copyright 2025 Alliance News Ltd. All Rights Reserved.